ADMA Biologics (ADMA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.16
- EPS estimate
- $0.16
- EPS surprise
- +0.98%
- Revenue surprise
- −0.76%
- Revenue
- $124.4M
- Revenue estimate
- $125.3M
- Reported
- Aug 5, 2026
ADMA Biologics reported Q2 2026 results on August 5, 2026. EPS was $0.16, 0.98% above the $0.16 estimate. Revenue of $124.4 million was 0.76% short of the $125.3 million consensus. Against Q2 2025, EPS rose 6.7% from $0.15 and revenue rose 2.0% from $122.0 million.
The table shows a move from losses to profits. ADMA lost $0.34 per share in 2022 and $0.12 in 2023, then earned $0.53 in 2024 and $0.66 in 2025, up 24.5%. Annual revenue rose from $154.1 million in 2022 to $510.2 million in 2025, about 3.3 times. Q4 2025 set the table highs at $0.21 per share and $139.2 million in revenue. Revenue then dipped to $114.5 million in Q1 2026 before recovering in Q2. First-half 2026 EPS was $0.33, against $0.29 a year earlier. ADMA beat EPS estimates in 14 of the 20 quarters, and in three of the last four.
Third-quarter results came between November 5 and November 10 in each year shown, most recently on November 5, 2025. That points to early November 2026 for Q3. The report will show how revenue compares with the $134.2 million of Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.16 | $0.16 | +0.98% | $124.4M | SEC |
| Q1 2026 | May 6, 2026 | $0.19 | $0.17 | −11.74% | $114.5M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.19 | $0.21 | +15.24% | $139.2M | SEC |
| Q3 2025 | Nov 5, 2025 | $0.15 | $0.16 | +9.43% | $134.2M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.14 | $0.15 | +7.75% | $122.0M | SEC |
| Q1 2025 | May 7, 2025 | $0.15 | $0.14 | −11.22% | $114.8M | SEC |
| Q4 2024 | Mar 3, 2025 | $0.15 | $0.14 | −6.07% | $117.5M | SEC |
| Q3 2024 | Nov 7, 2024 | $0.13 | $0.16 | +25.38% | $119.8M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.08 | $0.14 | +77.25% | $107.2M | SEC |
| Q1 2024 | May 9, 2024 | $0.06 | $0.09 | +62.00% | $81.9M | SEC |
| Q4 2023 | Feb 28, 2024 | $0.03 | −$0.08 | −420.00% | $73.9M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.01 | $0.01 | +233.33% | $67.3M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.03 | −$0.02 | +29.60% | $60.1M | SEC |
| Q1 2023 | May 10, 2023 | −$0.04 | −$0.03 | +29.41% | $56.9M | SEC |
| Q4 2022 | Mar 23, 2023 | −$0.07 | −$0.06 | +14.29% | $50.0M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.08 | −$0.08 | −3.23% | $41.1M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.08 | −$0.07 | +12.50% | $33.9M | SEC |
| Q1 2022 | May 11, 2022 | −$0.09 | −$0.13 | −52.94% | $29.1M | SEC |
| Q4 2021 | Mar 24, 2022 | −$0.09 | −$0.09 | +2.91% | $26.4M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.14 | −$0.13 | +6.00% | $20.7M | SEC |
Quarterly revenue
Frequently asked questions
When did ADMA Biologics (ADMA) last report earnings?
ADMA Biologics last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ADMA beat earnings estimates?
Yes. ADMA Biologics reported EPS of $0.16 for Q2 2026 against a $0.16 estimate — a 0.98% beat.
How much revenue did ADMA report last quarter?
ADMA Biologics reported $124.4M in revenue for Q2 2026, against a consensus estimate of $125.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.